




RealRate

PHARMACEUTICAL 2024

Talpheria INC
Rank 149 of 309

AcelRx
Pharmaceuticals, Inc.



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Talpheria INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Talpheria INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Talpheria INC is the variable Net Income, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 224%, being 11% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	11,556
Cost of Goods Sold	0
Intangible Assets	8,819
Liabilities, Current	4,512
Liabilities, Non-Current	0
Other Assets	20
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	1,778
Other Net Income	-1,508
Other Revenues	651
Property and Equipment	0
Research and Development	5,546
Selling, General and Administrative Expense	11,994

Output Variable	Value in 1000 USD
Assets	20,395
Liabilities	6,290
Expenses	17,540
Revenues	651
Stockholders Equity	14,105
Net Income	-18,397
Comprehensive Net Income	-18,397
BaseVar	23,192
ECR before LimitedLiability	93%
Economic Capital Ratio	224%